Daxor Corporation (DXR) Stock Price & Analysis
Daxor Corporation (DXR) closed at USD 10.2 on Thursday, October 15, 2026, up 1.75% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 10.03; the Oct 15, 2026 session ranged USD 10.08–10.36 on volume of 24,433 shares. Market capitalization is $59.55M, with a 52-week range of USD 8.56–14.76 (NCM). Source: Nexqual, retrieved October 16, 2026 at 05:21 UTC.
Also available as compact Markdown for AI agents: nexqual.com/DXR.md
Key facts (DXR)
- Analysts: Buy (mean 1.50 on a 1–5 scale) (2 analysts), mean target USD 20 (range 18–22).
- Total return with dividends: 1Y -21.5% vs S&P 500 +18.1%; 5Y -9.3% vs S&P 500 +85.1%.
Analysts (DXR)
Consensus Buy (mean 1.50 on a 1–5 scale), 2 analysts; mean target USD 20 (low 18, high 22).
Total return (dividends reinvested) (DXR)
| 1Y (from 2025-10-16) | 5Y (from 2021-10-11) | |
|---|---|---|
| Total return | -21.5% | -9.3% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -21.6% | -1.9% |
| Volatility (annualized) | 50.5% | 37.4% |
| Max drawdown | -39.9% (Dec 2025→Apr 2026) | -48.6% (Jul 2022→Feb 2025) |
Key Statistics (as of October 16, 2026 at 05:21 UTC)
| Price | USD 10.2 |
|---|---|
| Change | ▲ 1.75% (up) |
| Previous Close | USD 10.03 |
| Open | USD 10.36 |
| Day Range | USD 10.08 – 10.36 |
| 52-Week Range | USD 8.56 – 14.76 |
| Volume | 24,433 shares |
| Market Cap | $59.55M |
| Exchange | NCM |
Technical Analysis (DXR)
Nexqual's technical model rates DXR "SELL" based on 1 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:21 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 44.22 (neutral) |
| vs SMA50 | Below (USD 10.63) |
| MACD | -0.17 (negative) |
Analyst Ratings (DXR)
Wall Street analysts rate DXR "Buy" based on 2 analysts, with a mean price target of USD 20 (range USD 18–22), per Nexqual as of October 16, 2026 at 05:21 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 2 |
| Mean Target | USD 20 |
| High Target | USD 22 |
| Low Target | USD 18 |
| Buy / Hold / Sell | 2 / 0 / 0 |
Earnings (DXR)
| Revenue Estimate | $1.80M |
|---|
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Financials & Fundamentals (DXR)
| Total Revenue | $31,360 |
|---|---|
| Revenue Growth (latest quarter, YoY) | +25.50% |
| Gross Margin | +100.00% |
| Operating Margin | -4529.86% |
| Profit Margin | +19861.41% |
| ROE | +14.24% |
| Current Ratio | 2.88 |
| Total Debt | $0 |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Financial Health Score (DXR)
Nexqual rates Daxor Corporation's overall financial health "Weak" across five dimensions, as of October 16, 2026 at 05:21 UTC.
| Growth | Critical — Revenue -78% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — No data |
| Cash Flow | Weak — Operating cash flow -$8M (TTM) |
| Efficiency | Mixed — ROE 14%, ROA -2.6% |
Ownership (DXR)
| Insider Ownership | +49.50% |
|---|---|
| Institutional Ownership | +7.02% |
| Shares Outstanding | 5.84M |
| Float | 2.90M |
| Short % of Float | +0.23% |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Leadership (DXR)
Daxor Corporation is led by Michael Richard Feldschuh (age 56), Chairman, President & CEO, per Nexqual as of October 16, 2026 at 05:21 UTC.
| Chairman, President & CEO | Michael Richard Feldschuh (age 56) |
|---|---|
| CFO, Chief Compliance Officer & Corporate Secretary | Robert J. Michel (age 68) |
| Chief Scientific Officer & Director | Jonathan Adam Feldschuh (age 60) |
| Vice President of Development & Operations | Linda Cooper |
| Senior Vice President of Commercialization | Annette Plishka B.S.N. |
Major Backers & Investors (DXR)
Notable institutional backers of Daxor Corporation include Thompson, Siegel & Walmsley LLC, Aristides Capital, LLC, Renaissance Technologies, according to Nexqual as of October 16, 2026 at 05:21 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Thompson, Siegel & Walmsley LLC | 4.14% |
| Aristides Capital, LLC | 0.71% |
| Renaissance Technologies | 0.5% |
| Susquehanna International Group, LLP | 0.46% |
| Crescent Grove Advisors, Llc | 0.21% |
| Nano Cap New Millennium Growth Fund L P | 0.21% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 1.7% |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| KMTS | Kestra Medical Technologies, Lt | USD 28.68 | ▲ 6.34% |
| XRAY | DENTSPLY SIRONA Inc. | USD 8.83 | ▲ 3.76% |
| LMAT | LeMaitre Vascular, Inc. | USD 83.16 | ▲ 1.97% |
| ATRC | AtriCure, Inc. | USD 57.78 | ▲ 1.6% |
| WRBY | Warby Parker Inc. | USD 24.59 | ▼ 7.28% |
| PLSE | Pulse Biosciences, Inc | USD 45.59 | ▼ 6.08% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:21 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt